Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure
Dipak Kotecha(University Hospitals Birmingham NHS Foundation Trust), Andrew J.S. Coats(Fondazione Salvatore Maugeri), Hans Wedel(Sahlgrenska University Hospital), Josep Redón, Michael Böhm(Universitätsklinikum des Saarlandes), Frank Ruschitzka(Kantonsspital St. Gallen), John G.F. Cleland(University of Glasgow), John Kjekshus(Nuffield Health), John J.V. McMurray(British Heart Foundation), Marcus Flather(Royal Brompton Hospital), John Wikstrand(Nuffield Health), Milton Packer(Baylor University Medical Center), Kevin Damman(University Medical Center Groningen), Thomas G. von Lueder(Oslo University Hospital), Jane Holmes(University of Manchester), Giuseppe Rosano(British Lung Foundation), Dirk J. van Veldhuisen(University Medical Center Groningen), Luís Manzano(Universidad de Alcalá), Bert Andersson(Sahlgrenska University Hospital), Simrat Gill(University of Birmingham), Stefan D. Anker, Alan S. Rigby(University of Hull)
Cited by 67
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k